HONOLULU, Sept. 19, 2017 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) welcomes the findings of a clinical study recently published in the New England Journal of Medicine that validate the crucial role inflammation plays in cardiovascular health. The 10,000 patient, double-blind, placebo-controlled study ("CANTOS") sponsored by Novartis demonstrated, for the first time in history, that an anti‑inflammatory drug reduced major adverse cardiovascular events—independent of cholesterol levels.
The study supports the opportunity Cardax sees for its astaxanthin supplement ZanthoSyn® to manage cardiovascular inflammatory health with substantial safety and cost benefits compared to the agent used in this study.
While this study does not prove that other anti-inflammatory approaches will have similar benefits in cardiovascular health, cardiovascular experts not involved in the trial have pointed to the broad potential application of this study to support the use of other anti-inflammatory agents.
For example, Cleveland Clinic's heart chief, Dr. Steven Nissen, was quoted by the Washington Post as saying, "It (this study) opens up an entirely new vista for the treatment of heart disease, because now everybody on the planet—in the pharmaceutical industry and in research institutions like ours and at the National Institutes of Health—are going to be looking to find anti-inflammatory therapies." (Emphasis added by Cardax.)
We believe that an ideal anti-inflammatory solution for the large cardiovascular health market should provide:
- Reduction of CRP, the primary inflammatory measurement in the CANTOS study
- Reduction of IL-1ß, a key inflammatory mediator and target of the CANTOS study drug, canakinumab
- Reduction of IL-6, a key inflammatory mediator reduced in the CANTOS study
- Reasonable Pricing
ZanthoSyn®, Cardax's non-pharmaceutical astaxanthin supplement for cardiovascular health, meets all of these criteria:
- Safety: Astaxanthin, the active ingredient in ZanthoSyn, has undergone extensive safety testing and is Generally Recognized as Safe ("GRAS") according to FDA regulations—a safety designation traditional anti-inflammatories for cardiovascular health do not have.
- Inflammatory Health: More than 1,500 peer-reviewed papers and 50 Phase II type human clinical trials support the use and safety of astaxanthin, the active ingredient in ZanthoSyn. Specifically, astaxanthin has demonstrated statistically significant reduction in:
- CRP in humans1
- IL-1ß in animals2
- IL-6 in animals3
- TNF-α, another important mediator of inflammatory health, in humans4
- TNF-α equivalent to prednisolone in animals5
- Pricing: ZanthoSyn only costs $39.99 per 60 capsule bottle and is widely available through General Nutrition Corporation ("GNC") stores.
ZanthoSyn® 2.0 connects cardiovascular inflammation and longevity:
CDX-085, Cardax's next generation ZanthoSyn astaxanthin supplement, was recently chosen by the National Institutes of Health as a top anti-aging prospect for its impact on FOXO3, an important longevity gene that targets cardiovascular inflammation. This selection resulted from a study at the University of Hawaii demonstrating the ability of CDX-085 to increase FOXO3 activation by 90%. Cardax is developing CDX-085 as an "extra strength" astaxanthin supplement and exploring pharmaceutical applications.
"The CANTOS study confirmed that reducing inflammation improves cardiovascular health, underscoring the basis on which Cardax was founded," said Cardax CEO, David G. Watumull. "We believe that scientifically addressing cardiovascular inflammatory health offers a transformative opportunity, perhaps unmatched in the industry in many years."
- Park JS et al., 2010. Nutrition & Metabolism, 7: 18.
- Lee SJ et al., 2003. Molecules and Cells, 16(1): 97-105.
- Izumi-Nagai K et al., 2008. Investigative Ophthalmology and Visual Science, 49(4): 1679-1683.
- Uchiyama A and Okada Y, 2008. Journal of Clinical Biochemistry and Nutrition, 43(Suppl 1): 38-43.
- Ohgami K et al., 2003. Investigative Ophthalmology and Visual Science, 44(6): 2694-2701.
Cardax devotes substantially all of its efforts to developing and commercializing safe anti-inflammatory dietary supplements and drugs. Cardax is initially focusing on astaxanthin, which is a powerful and safe naturally occurring anti-inflammatory without the side effects of currently marketed anti-inflammatories. The safety and efficacy of Cardax's products have not been directly evaluated in clinical trials or confirmed by the FDA.
ZanthoSyn is a physician recommended anti-inflammatory supplement for health and longevity that features astaxanthin with optimal absorption and purity. ZanthoSyn is sold online and in GNC stores. ZanthoSyn contains astaxanthin, which is Generally Recognized as Safe (GRAS) according to FDA regulations.
Astaxanthin is a clinically studied compound with safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, liver health, and longevity.*
Media and Investors
This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
View original content with multimedia:http://www.prnewswire.com/news-releases/cardax-welcomes-cardiovascular-research-breakthrough-300521786.html
SOURCE Cardax, Inc.